Polycomb repressive complex’s evolutionary conserved function: the role of EZH2 status and cellular background by Gall Trošelj, Koraljka et al.
REVIEW Open Access
Polycomb repressive complex’s
evolutionary conserved function: the role of
EZH2 status and cellular background
Koraljka Gall Trošelj1*, Renata Novak Kujundzic1 and Djurdjica Ugarkovic2
Abstract
When assembled in multiprotein polycomb repressive complexes (PRCs), highly evolutionary conserved polycomb group
(PcG) proteins epigenetically control gene activity. Although the composition of PRCs may vary considerably, it is well
established that the embryonic ectoderm development (EED) 1, suppressor of zeste (SUZ) 12, and methyltransferase
enhancer of zeste (EZH2)-containing complex, PRC2, which is abundant in highly proliferative cells (including cancer cells),
establishes a repressive methylation mark on histone 3 (H3K27me3). From the perspective of molecular cancer
pathogenesis, this effect, when directed towards a promoter of tumor suppressor genes, represents pro-tumorigenic
effect. This mode of action was shown in several cancer models. However, EZH2 function extends beyond this scenario.
The highly specific cellular background, related to the origin of cell and numerous external stimuli during a given time-
window, may be the trigger for EZH2 interaction with other proteins, not necessarily histones. This is particularly relevant
for cancer.
This review provides a critical overview of the evolutional importance of PRC and discusses several important aspects of
EZH2 functioning within PRC. The review also deals with mutational studies on EZH2. Due to the existence of several
protein (and messenger RNA (mRNA)) isoforms, these mutations were stratified, using the protein sequence which is
considered canonical. This approach showed that there is an urgent need for the uniformed positioning of currently
known EZH2 mutations (somatic—in tumors, as well as germline mutations in the Weaver’s syndrome).
Finally, we discuss EZH2 function with respect to amount of trimethylated H3K27, in a specific cellular milieu, through
presenting the most recent data related to EZH2-H3K27m3 relationship in cancer. All these points are significant in
considering EZH2 as a therapeutic target.
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Background
Post-translational modifications (PTMs) of histone poly-
peptides contribute to the regulation of gene activity
through establishing a specific epigenetic regulatory
network [1]. Partly due to PTMs of histones, poly-
comb group (PcG) proteins can control gene silencing
in a considerable part of the genome but only when
assembled in multiprotein polycomb repressive com-
plexes (PRCs)—polycomb (Pc)-containing complexes
(PRC1) and the enhancer of zeste-containing com-
plexes (PRC2/PRC3/PRC4) [2, 3]. These complexes
are responsible for the epigenetic memory of gene
expression states and play a crucial role in the main-
tenance and reprogramming of cell types during normal
development and during pathophysiological processes
(reviewed in [4]).
Enhancer of zeste-containing complexes during evolution
Originally identified in the fruit fly Drosophila melanogaster
as crucial factors in maintaining the repressed state of
developmental regulators such as homebox HOX genes [5],
the Pc-group proteins were shown to be highly evolutionary
conserved [6]. For example, PRC2 is detected even in uni-
cellular eukaryotes, alga Chlamydomonas [7] and yeast
Cryptococcus neoformans [8].
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The widespread presence of PRC2, from unicellular or-
ganisms to humans, points out its significance for pre-
serving a specific module(s) of gene repression.
Evolutionary processes have offered unique ways of
PRC2 composing (Table 1): (1) Drosophila contains four
core proteins: enhancer of zeste E(Z); suppressor of zeste
12 SU(Z)12; extra sex combs (ESC) and the histone
binding protein p55. The E(Z) protein contains a SET
domain which exerts histone lysine methyltransferase
activity (KMT), able to catalytically add up to three me-
thyl groups at the target lysine residue K27 of histone 3
(H3). The E(Z) possesses the SANT domains involved in
histone binding and a C5 domain required for interact-
ing with SU(Z)12 [9]; (2) Yeast Cryptococcus neoformans
PRC2 has no homolog of SU(Z)12 but contains two add-
itional proteins, Bnd1 and Cc1, specific for this species
[8]; (3) In nematode Caenorhabditis elegans, only homo-
logs of E(Z) and ESC are found, MES-2 and MES6, re-
spectively. These two proteins make a PRC2 together with
a MES-3 protein which has no homolog in any other model
organism, and such complex is involved in X-chromosome
repression [10]; (4) Plants such as Arabidopsis thaliana,
due to gene duplications, have three homologs of E(Z):
CLF, MEA, SWN; three homologs of SU(Z)12: FIS, VRN2,
EMF2; and five homologs of p55: MSI1-5, while only one
homolog of ESC is present (reviewed in [11]). The combi-
nations of these proteins make at least three distinct PRC2
which are involved in different developmental processes.
FIS-PRC2 is similar to its mammalian counterpart and reg-
ulates expression of imprinted genes and cell proliferation.
EMP-PRC2 acts like Drosophila and mammalian PRC2 in
maintaining the repressed state of homeotic genes and, to-
gether with the third complex, VNR-PRC2, regulates flower
time [11] .
The duplication of E(Z) gene resulted in two mammalian
E(Z) proteins, EZH1 and EZH2 (Table 1), as well as two
PRC2 complexes, each containing one of these two EZH-
proteins. Accordingly, mammalian PRC2 is composed of
four core subunits: EZH1/EZH2, SUZ12, embryonic ecto-
derm development (EED), and retinoblastoma(Rb)-associ-
ated protein 46/48 (RbAp46/48).
Although present in similar PRC2 complexes and con-
trolling an overlapping set of genes, EZH1 and EZH2 are
considerably different. PRC2-EZH2, abundant in highly
proliferative cells, establishes a repressive H3K27me3
mark on PRC2 target genes. PRC2-EZH1, which is abun-
dant in non-dividing cells, likely restores this repressive
mark, either as a result of its disappearance due to de-
methylation or by histone exchange [12].
PRC composition is flexible and cell-type specific
H3K27 is not the only histone-related substrate for
EZH2, as the PRC-partners may direct the EZH2 to
other substrates. For example, an EED isoform 2 (Eed2)
and NAD-dependent histone deacetylase Sirt1 specific-
ally associate within the PRC4 which is needed for
methylating linker histone H1 (H1K26) [13]. This modifi-
cation is specific for cancer and undifferentiated embry-
onic stem (ES) cells.
There is a whole spectrum of variations relating to the
dynamic exchange of protein partners (AEBP2, Pcl1/2/3
(PHF1/MTF2/Pcl3t), Jarid2) which may be temporary
members of PRC2. This “exchange phenomenon” should
not be surprising, as the specific biological effect medi-
ated by PRCs—broad control of gene activity must be
achieved very precisely, in a cell-type specific manner
and during a controlled time-window (Fig. 1) [14]. For
example, Jarid2—a member of Jumonji family of histone
demethylases without enzymatic activity—was identified
as a part of PRC2, in interaction with Ezh2. Jarid2 binds
DNA with a slight preference for GC rich sequences
[15] and recruits PcG proteins to target genes [16].
Although there are several possibilities related to flexible
ways of composing the content of PRC2 (as discussed), it
Table 1 PRC2 core proteins in model organisms [4, 8]
Yeast Crytococcus
neoformans
Nematode
Caenorhabditis
elegans
Plant Arabidopsis
thaliana
Fly Drosophila
melanogaster
Mouse and human
Mus musculus and
Homo sapiens
Bnd1, Cc1
MES-3
EED1 MES-6 FIE ESC EED
EZH2 MES-2 CLF E(Z) EZH1
MEA EZH2
SWN
FIS2 SU(Z)12 SU(Z)12
VRN2
EMF2
MSI1 MSI1-5 p55 RbAp46/48
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is known that the minimum components required for
methyltransferase activity of the PRC2/EED-EZH2 com-
plex are EED, EZH2, and SUZ12. The coordinated activity
of these proteins is essential for establishing di- and tri-
methylated H3K27 (H3K27me2/me3) marks which are as-
sociated with facultative heterochromatin. These marks
present the hallmark histone modification produced by
Ezh1 and Ezh2 activity within the PRC2. However, the
precise mechanism that governs PRC2 recruitment to
chromatin in mammals still needs to be defined.
Recognizing PRC2 functioning as a holoenzyme whose
components act together to establish interaction with
chromatin in a stepwise manner, Margueron and Rein-
berg [17] have proposed the following several-steps
model: (a) interaction of Jarid2 and AEBP2 with DNA
[18, 19]; (b) interaction of RbAp46/48 with histones H3
and H4 [20]; (c) interaction of Eed with H3K27me3 [21];
(d) interaction of Plcs with an unknown histone mark;
and (e) interaction of PRC2 subunits with long non-
coding RNA (lnc RNA).
These molecular events are highly conserved. In mam-
mals (reviewed in [22]) are well documented through
the interaction of lnc RNA X inactive-specific transcript
(Xist) with EZH2 and the consequential recruitment of
PRC2 to the X-chromosome leading to its inactivation.
In plants, cold induced lnc RNA COLDAIR interacts
with plant E(Z) homolog CLF [23] and recruits PRC2 to
the target locus in a way similar to the Xist in mammals.
In malignant neoplasms, as shown in gastric cancer,
overexpressed lnc RNA 00152 needs to bind to EZH2 in
order to exert oncogenic potential through recruiting
the PRC2 to promoters of tumor suppressor (TS) genes
p15 and p21 [24].
Learning about the evolutional significance of PRC2 in
the control of cellular proliferation and differentiation is
very important for understanding some basic patho-
physiological processes. For example, plants with double
mutation of two out of three E(Z) homologs, clf and
swn, undergo normal seed development, but produce a
mass of proliferating, undifferentiated tissue resembling
cancer, instead of a differentiated shoot after germin-
ation [25].
Several aspects of aberrant EZH2 function in cancer
In humans, the EZH2 mutation may occur in a germline,
resulting in clinical features known as the Weaver syn-
drome, originally described in 1974 [26]. In 2011, muta-
tional analysis of EZH2 in 48 Weaver syndrome
patients revealed 44 missense and four truncated mu-
tations. All but two SET domain mutations (R684C
and S652C), which were present in five and two
unrelated individuals, respectively, were distributed
throughout the gene, without specific clustering [27].
Only two germline EZH2 mutation-positive individ-
uals developed hematological malignancies: E745K (a
lymphoma diagnosed at the age of 13) and an A682T
mutation (acute lymphoblastic leukemia (ALL) and
neuroblastoma developed at 13 months).
PRC3
PRC3
EZH2
SU(Z)12
RbAp46/48
EED2EED1
PRC2 PRC4
EED3+4
SIRT1
Histone H1- Histone H1-
Histone H1+ Histone H1+
Histone H1+Histone H1-
H3K27
H1K26
H3K27
H1K26
H3K27
Fig. 1 Association of PRC-EZH2 complexes with different EED isoforms in the presence (H1+) or absence (H1−) of linker histone H1 directs EZH2-
mediated methylation towards H3K27 or H1K26. PRC2, which contains the longest form of EED (EED1), is able to methylate isolated histone H3.
When targeted to oligonucleosomes containing linker histone H1, PRC2 methylates histone H1 rather than histone H3. PRC3, containing EED3
and EED4, methylates nucleosomal histone H3, but its methyltransferase activity is inhibited by histone H1. PRC4, containing EED2 and NAD-
dependent deacetylase SIRT1, methylates histone H1 when present, but has also low methylating capacity towards H3K27 in the absence of
histone H1 (depicted in gray) [13, 14]
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In 1996, EZH2 was first discovered as a binding part-
ner of Vav oncoprotein in hematological malignancies
[28]. These neoplasms were, in addition to breast and
prostate cancer, pioneering models for investigating
the function and role of EZH2. Its overexpression was
first associated with amplification at 7q35 (more than
four EZH2 copies per cell) in approximately 15 % of
the 225 analyzed breast cancers (BCs) [29]. In 2010,
EZH2 point mutation (Y641) in SET domain was first
found in 7 % of large follicular lymphomas and 22 %
of diffuse B cell lymphomas [30]. It was also found in
approximately 3 % of melanomas [31]. The discovery
of two additional SET domain mutations (A677G and
A687V) followed [32, 33].
These “gain of (methyltransferase) function” mutations
are responsible for the oncogenic mode of EZH2 action.
Contrary to wild-type (WT) EZH2, which loses activity
when progressively more methyl groups are incorporated
into H3K27, all tested Y641 mutant enzymes (Y641F/N/
S/H/C) displayed the opposite trend (H3K27me0:-
me1:me2 kcat/Km ratio: 13:4:1 (WT) vs 1:2:22 (Y641)
[34]. Since one cell possesses both wild- and mutant
types of the EZH2 allele, there appears to be dependency
on the coordinated activity of both alleles.
Aberrant activity of PRC2 can result from aberrant
EZH2 expression, without chromosomal amplification,
as a consequence of diverse aberrations which are
present in cancer cells. For example, comprehensive ana-
lyses of transcriptome and epigenome data obtained
from adult T cell leukemia (ATL) cell lines, normal CD4
+T cells, human T-lymphotropic virus type 1 (HTLV-1)-
immortalized and transformed T cells show the import-
ance of increased, NF-κB dependent expression of EZH2
(both RelA and RelB were shown to be bound to EZH2
promoter) which further activates NF-κB through silen-
cing of microRNA (miR)-31. Of interest for this model,
H3K27me3 was enriched in the promoter of tran-
scriptionally downregulated H3K27me3 demethylase
KDM6B (JMJD3), which also may compromise the
balance between epigenetic “writers” and “erasers.” It
was shown that HTLV-1 protein Tax binds to EZH2,
without affecting the PRC2 composition. As a result,
the pattern of H3K27me3 accumulation significantly
overlaps in ATL- and HTLV-1-immortalized cells.
Since HTLV-1 infected cells are sensitive to EZH2 in-
hibition, this research data may be a ground for
introducing EZH2 inhibitors for treating asymptom-
atic, HTLV-1 infected individuals [35].
Hepatitis B virus (HBV)-associated hepatocellular can-
cer (HCC) represents another interesting model for
studying the abberant expression of tumor suppresive
miRs in respect to PRC2 activity in a setting of pro-
longed viral infection. In the HBV-HCC model, co-
expression of transcription factor (TF) YY1 and EZH2
are associated with silencing several, multiple YY1 bind-
ing sites-containing suppressive miRs and relate to short
disease-free survival [36]. YY1 can interact with both
EZH2 and SUZ12 [37] and recruits the PRC2 complex
to chromatin. The discovery of this oncogenic mechan-
ism, which was responsible for silencing of five highly
NF-κB suppresive miRs, pointed out the importance of
coordinated action of YY1 and EZH2 for focal reshaping
of chromatin.
The already mentioned tumor suppressor miR-31 was
shown to be silenced in prostate cancer cells through
presence of H3K27me3 on its promoter [38]. The ab-
sence of miR-31 in t(4;14) positive multiple myeloma
(MM) patients (15–20 %) allows for pro-oncogenic ac-
tivity of its target—multiple myeloma set domain meth-
yltransferase (MMSET), which establishes histone mark
H3K36me2 and induces a global reduction H3K27me3
[39]. However, in this scenario, specific loci exhibit en-
hanced recruitment of EZH2, leading to misregulation of
specific polycomb target genes.
It was recently shown that H3K27me3 enriched genes
in experimental models of MM significantly overlap with
underexpressed genes in MM patients with poor survival
[40]. Of interest, although applying EZH2 inhibitor,
E7438 induces reproducible re-expression of crucial
epithelial tumor suppressor genes (including CDH1) in
13 tested MM cell lines, there are many questions aris-
ing from a high variability in E7438 sensitivity in the
proliferation assays [41].
All these examples show that there are many factors
that may influence EZH2 and are influenced by EZH2.
Accordingly, EZH2 pharmacological inhibition may have
various effects.
In addition to “gain of function” mutations, there are
also EZH2 “loss of function” mutations discovered in
hematological malignancies originating from myeloid
cells, commonly joined with unipaternal disomy (UPD)
[42]. The proposed model of EZH2 “loss of function” mu-
tations (of which the majority were found in the SET do-
main) attributes their contribution to be forming cancer
stem cells, via HOXA9 mediated self-renewal of myeloid
progenitors. A complex in vivo model (transplantation of
bone marrow (BM) cells from 8–12-week-old Cre-
ERT;Ezh2fl/fl CD45.2 mice into lethally irradiated CD45.1
recipient mice and deletion of Ezh2 at 6 to 8 weeks post-
transplantation) reveals that complete lack of EZH2 activ-
ity in hematopoietic stem cells (HSCs) predisposed mice
to heterogenous malignancies (MDS, MDS/MPN, MDS/
MPN associated with trombocytosis, and T cell acute
lymphoblastic leukemia). The same experimental model
showed locus-specific repositioning of EZH1 to EZH2 tar-
gets (3605 genes in contrast to 969 “EZH2 targets only”)
and its ability to re-repress them during prolonged period
of time (9 months) [43]. All these data clearly indicate that
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EZH2 function, in both physiological process and in
various pathogenic events, must be studied in a broad
context, keeping in mind that its binding partners contrib-
ute to specificity of its functioning, in a particular cellular
setting.
Which mutation is “the right one”?
The problem that occurs when comparing the results of
EZH2 mutational analyses coming from different
sources relates to amino acids positioning in the EZH2
sequence. For example, “gain of function” mutations are
listed according to the protein sequence that is consid-
ered “canonical” (UniProtBD/Swiss-Prot Q 15910–1; 746
amino acids (AA)) [30, 32, 33]. On the other hand, “loss
of function” [34], and germline mutations [27], were po-
sitioned according to the longest protein isoform of
EZH2 (UniProtBD/Swiss- Prot Q 15910-2; 751 AA). The
absence of uniformity may be confusing. For example,
the already mentioned inherited mutation discovered in
the Weaver syndrome patient suffering from ALL
(A682T) [27] corresponds to alanine 677 mutation
(A677G) in B cell lymphoma [30]. Similarly, a rare
EZH2 breast cancer mutation described as A692V [44]
corresponds to B cell lymphoma mutation at position
687 [33]. The difference of five amino acids corresponds
to the difference between Q15910-1 and Q15910-2 iso-
forms (HP→HRKCNYS), which are identical in the first
297 amino acids (Fig. 2). The basic data on currently
known EZH2 protein isoforms and their coding messen-
ger RNAs (mRNAs) are presented in Table 2. The hope
is that future presentations of EZH2 isoforms and the
positions of mutated codons will be done in a more uni-
form manner.
Stratified presentation of mutations published in previ-
ous studies [27, 30–34, 44] reveals identical type/pos-
ition of three germline (G) and three somatic (S)
mutations. One mutation was reported as oncogenic
(lymphoma; S&G:A677T), and two other ones were re-
ported as suppressive (S:E741fs→G:E741K; S:R679C/
P→G:R679C/H) (Fig. 2; UniProtBD/Swiss- Prot Q
15910-1). It remains to be seen whether any of these
EZH2 mutations act as a “Janus” mutation in the RET
protooncogene (germline mutation that acts simultan-
eously as both a gain-of-function and a loss-of-function
mutation) [45].
Data related to the functional differences of EZH2
splice variants is scarce. The expression level of EZH2
transcript variants 1 and 3 was shown to be similar in 22
tested human tissue samples. Forced expression of cor-
responding protein isoforms (Q 15910-2 and Q 15910-3;
Table 2) in pancreatic cancer cells revealed that each
protein isoform has an affinity for a preferential gene
cluster (36.3 and 47.6 % genes were repressed by EZH2β
(Q 15910-3) and EZH2α (Q 15910-2), respectively, while
repression of remaining 16.1 % genes needed the pres-
ence of both isoforms) [46]. The data indicates that the
different EZH2 cell-specific mRNAs, and protein iso-
forms may have functional importance, including for the
clinic, as already shown for some other genes [47, 48].
Specific cellular background and multiple roles of EZH2
EZH2 binding affinity for both histones and non-histone
substrates may partially explain why targeted silencing
of EZH2 leads to bidirectional change of gene expres-
sion, in a specific cellular context-dependent manner
[49]. Some examples are: (1) EZH2 binds to RelA/RelB
in BC cells and regulates the NF-κB target genes in a posi-
tive (IL-6, TNF) or negative way, depending on estrogen
receptor (ER) status rather than the EZH2 histone methyl-
transferase activity. In ER+ BC cells, ER recruits PRC2 for
enforcing a repressive chromatin modification at NF-κB
target genes. (2) In squamous cell carcinomas (SCC),
EZH2, through repressing IκB kinase α (IKK1) promoter,
leads to IKK1 silencing [50]. In any other types of tumor,
this would be a suppressive effect. However, it is onco-
genic in SCCs because IκB kinase α has a tumor suppres-
sive role in these tumors [51]. 3. Finally, it seems that
EZH2 catalytical activity does not have the most signifi-
cant role for an increased rate of growth in some SWI/
SNF-mutant cancers [52]. Instead, the stabilization of
PRC2, dependent on EZH2 threonine 487 (T487)
phosphorylation (Prot Q 15910-1), seems to be essen-
tial, at least in this particular scenario [53]. However,
this phenomenon may be abrogated by presence of
mutant K-ras.
In non-small cell lung cancer (NSCLC), the type of
substitution at 12th codon of K-ras determines activa-
tion of a specific pro-proliferative signaling pathway.
Cells with K-RAS G12D/+ or K-RAS G12C/+ have primarily
activated PI3/AKT and MEK/ERK signaling pathways,
respectively [54]. Accordingly, activation of EZH2, which
was shown to be dependent on K-ras mutants, may be
inhibited by specific inhibitors of mutation-type
dependent downstream signals. This is important be-
cause one of significant pro-oncogenic activities of
EZH2 depends on activated AKT which, through EZH2,
phosphorylates and activates oncogenic STAT3 [55] .
A generation of mice with Cre-recombinase-activated
conditional oncogenic K-ras allele (K-ras G12D/+), along
with either mild Ezh2 overexpression (Ezh2LSL) or lost
PRC2 function achieved by conditional deletion of Eed1
(Eedfl/fl), joined with conditional deletion of p53
(Trp53fl/fl), revealed that the genotype K-rasG12D/+;
Trp53fl/fl; and Eedfl/fl develops the most aggressive, mu-
cinous NSCLC. In this genetic setting, which is relevant
for human pathology (mutations of K-RAS and P53 are
present in 35 and 40 % NSCLCs, respectively), Eed1 acts
as a tumor suppressor gene. In the presence of WTp53,
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Fig. 2 (See legend on next page.)
Gall Trošelj et al. Clinical Epigenetics  (2016) 8:55 Page 6 of 10
KrasG12D/+;Eedfl/fl mice developed NSCLs which were,
although smaller than KrasG12D/+ /Ezh2LSL tumors,
characterized by life incompatible inflammation in alvelo-
lar spaces. In vitro, the inhibition of EZH2, achieved
through the prolonged exposure of human K-RAS-
mutant NSCLC cells to an inhibitor of EZH2 catalytic
activity (GSK126), resulted in a strong increase of
inflammatory genes (i.e., IL-6) associated with
microenvironment-regulated tumor progression. Based
on these and many more results coming from the cited
study [56], it was suggested that PRC2 can hold oppos-
ing functions, depending on the stage of tumor
development and the genetic make-up of the tumors
(as presented here), with respect to p53 status. Accord-
ingly, this and other studies clearly show a rationale for
the combined application of PRC2 inhibitors and anti-
inflammatory drugs. In the model of hematopoietic
stem cells, EZH2 loss was recently shown to result in
the expression of fetal gene signature, including upreg-
ulation of fetal-specific Lin28b which encodes RNA-
binding protein that prevents maturation of miR-let-7
which is specific for adult HSCs. Activation of fetal
gene signature in EZH2-deficient adult bone marrow
HSCs was shown to result in fetal-like high self-renewal
capacity and increased propensity to undergo malignant
transformation [57]. Enforced expression of Lin28b has
been reported to impair T cell development in vivo,
leading to developing an aggressive peripheral T cell
lymphoma, accompanied by a decrease in let-7 expres-
sion, surge of IL-6, activation of NF-κB, and infiltration
of B cells leading to an inflammatory microenviron-
ment [58].
The proper anti-tumor function of T cells depends on
the differentiation of naive and memory T cells into ef-
fector cells. Metabolic switch from oxidative phosphoryl-
ation to aerobic glycolysis is mandatory for T cell
activation. Highly glycolytic ovarian cancer cells were re-
cently shown to impose glucose restriction on tumor-
infiltrating T cells, thereby inhibiting this metabolic
switch. Low glucose availability results in upregulation
of EZH2-targeting miR-26a and miR-101 with subse-
quent EZH2 downregulation. This is consequential for T
cell effector function, since EZH2 activates the Notch
pathway that stimulates T cell polyfunctional cytokine
expression and their survival, which was shown to be
impaired in many tumors. These results point to the dif-
ferent effects that systemic inhibition of EZH2 may have
on tumor cells and T cells, warranting special caution
when considering such epigenetic intervention [59].
H3K27me3 as a measure of EZH2 activity
There are many EZH2-related scenarios and none of
them is simple. When analyzed in five well-defined sub-
types of BC, the highest EZH2 expression, joined with a
very low level of H3K27me3, was found in basal-like,
triple negative BC [60], known for its distinctly aggres-
sive nature [61]. This inverted pattern (EZH2↑,
H3K27me3↓), further confirmed in a basal-like BC cell
lines, represents the negative prognostic marker in BC
patients [60, 62]. There are a few studies in which a
Table 2 Human EZH2: five proteins and corresponding mRNA splice variants are currently deposited. Although mutational
analyses of EZH2 refer to the ordinal number of mutated amino acids, they rarely identify the isoform which is the basis for
numbering them
UniProtBD/
Swiss-Prot
Transcript
variants (TV)
mRNA NCBI mRNA
length (nt)
Coding region cDNA l
ength (nt)
Protein
size (AA)
15910-1 TV3 NM_001203247.1 2708 194-2434 2241 746
15910-2 TV1 NM_004456.4 2723 194-2449 2256 751
15910-3 TV2 NM_152998.2 2591 194-2317 2124 707
15910-4 TV4 NM_001203248.1 2681 194-2407 2214 737
15910-5 TV5 NM_001203249.1 2682 321-2408 2088 695
(See figure on previous page.)
Fig. 2 Alignment of five EZH2 isoforms protein sequences (UniProt). SET domain is shown in green (Q15910-1 AA 612–727; Q15910-2 AA 617–
732; Q15910-3 AA 573–688; Q15910-4 AA 603–718; Q15910-5 AA 561–676). Germline mutations [27] are shown in orange, “loss of function” muta-
tions [42] in blue, and “gain of function” mutations [26, 30, 32, 33, 44] in red. All mutations listed in the cited references are marked on respective
isoform sequences, highlighting the lack of uniformity in annotating mutations according to consensus sequence (Q15910-1). Therefore, mutation
A677 (in isoform 1) is listed as somatic, activating mutation and at the same time, annotated as mutation A682 (in isoform 2), has been listed as
germline mutation which was discovered in the Weaver syndrome patient who developed ALL and neuroblastoma in early childhood. This is in
accord with the oncogenic potential of this mutation. Inactivating mutations R684 in isoform 2 (corresponding to R679 in isoform 1) and E745 in
isoform 2 (corresponding to E740 in isoform 1) have been shown to be mutated in Weaver syndrome patients. None of the five patients with inherited
mutation R684C (present as somatic mutation in one 82-year-old patient suffering from chronic myelomonocytic leukemia) developed malignant
disease at the time of testing for germline mutation of EZH2. Germline mutation E745K (isoform 2) was present in a patient who developed non-
Hodgkins lymphoma at the age of 13. Somatic mutation of this codon was detected in one patient with chronic myeloic leukemia during blast crisis.
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decreased level of H3K27me3 was associated with a poor
outcome in different malignant tumors (breast, ovary,
pancreas, lung) [63, 64]. These results, together with those
showing that solid tumors (prostate, breast) can develop
even in the absence of Ezh2 [44], challenge the strength of
EZH2 as the epigenetic driver of oncogenesis [65], at least
in the stated tumor types. This data, supported by a broad
analysis of human transcriptome data sets (131 prostate
cancers (plus 19 metastases), 146 BCs) indicates that EZH2
expression “follows” the rate of cellular division, is under
control of proliferation cues, and “passively” correlates with
proliferation and proliferation markers (primarily Ki-67), in
order to maintain the cellular level of H3K27me3.
It was suggested that EZH2 overexpression should be
considered from two perspectives: (a) through coupling
its expression to proliferation and (b) coupling it to
proliferation-independent, amplification-related, copy
number-driven, expression [44].
However, this approach should be considered in a spe-
cific cellular milieu and should not be applied non-
selectively, to all types of malignant tumors:
In many systems, EZH2 supports stem cell mainten-
ance by repressing differentiation. But, in neural crest
stem cells (NCSCs), which are the source of melano-
cytes, it specifically promotes the acquisition of a mesen-
chymal fate [66]. EZH2 is essential for melanoma
initiation and growth, during which EZH2 and Ki-67
positive cells significantly correlate, just like in the BC
model. Increased expression of EZH2 in melanoma
strongly correlates with shorter overall survival (OS) and
earlier development of distant metastases [67, 68].
EZH2-mediated repression of the tumor suppressor ade-
nosylmethionine decarboxylase 1 (AMD1) appears to be
of the greatest importance for these processes. The role
of this gene, as well as its repressor, EZH2, needs to be
further investigated and validated.
Conclusions
The function of any biomolecule must be considered in a
specific cellular setting. Accordingly, cell-type specific
signals which constantly change during adaptive responses
to various stimuli are the basis of an epigenomic dynamic
network, reflecting both—the type of the cell and the type
of the stimulus in a given time-window. Understanding
the exact role of EZH2 in such a complex system is not an
easy task. There is convincing mechanicistic data con-
firming the oncogenic function of EZH2 related to PRC2
functioning (repression of tumor suppressor genes through
H3K27me3) in several biological models. Numerous
studies, however, interpret an increased EZH2 immunore-
activity score as an unquestionable oncogenic event. The
fact that the score does not necessarily reflect the presence
of a functional PRC2 and/or its increased recruitment to
chromatin seems to be all too often neglected.
When considering EZH2 as a therapeutic agent, one
must take into account these parameters, together with an
understanding of the functional consequences of EZH2
mutations and the cancer patient’s specific cellular oncome-
tabolome with respect to systemic inflammatory reactions.
While the targeted inhibition of EZH2 catalytic activity
emerges as a promising therapeutic intervention, it still
has many other cellular-specific functions which must be
carefully evaluated to avoid broad side effects. These is-
sues are further discussed in a broader context elsewhere
in this issue of Clinical Epigenetics [69].
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